Molecular diagnosis of a BRAF papillary thyroid carcinoma with multiple chromosome abnormalities and rare adrenal and hypothalamic metastases

Thyroid

Volumn 16, Issue 12, 2006, Pages 1293-1302

  Copland, John A ^a   Marlow, Laura A ^a   Williams, Sandra F ^a   Grebe, Stefan K ^b   Gumz, Michelle L ^a   Maples, William J ^a   Silverman, Victor E ^c   Smallridge, Robert C ^a  

^a MAYO CLINIC   (United States)

^b Mayo Clinic   (United States)

^c Center for Medicine Endocrinology and Diabetes   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

17 ALLYLAMINOGELDANAMYCIN; CYTOKERATIN 7; DEPSIPEPTIDE; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; GELDANAMYCIN; MEVINOLIN; PACLITAXEL; SODIUM IODIDE SYMPORTER; THYROGLOBULIN; THYROID TRANSCRIPTION FACTOR 1; THYROTROPIN RECEPTOR; UNCLASSIFIED DRUG;

ADRENAL METASTASIS; ADULT; ALLELE; ARTICLE; CASE REPORT; CHROMOSOME ABERRATION; CHROMOSOME TRANSLOCATION 1; CHROMOSOME TRANSLOCATION 13; CHROMOSOME TRANSLOCATION 17; CHROMOSOME TRANSLOCATION 18; CHROMOSOME TRANSLOCATION 9; CONTROLLED STUDY; CYTOGENETICS; DNA SEQUENCE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOTHALAMUS TUMOR; IMMUNOCYTOCHEMISTRY; KARYOTYPE; LUNG CARCINOMA; LUNG NODULE; LYMPHADENOPATHY; MALE; MEDIASTINUM LYMPH NODE; MEDIASTINUM METASTASIS; MOLECULAR BIOLOGY; MOLECULAR MODEL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THYROID PAPILLARY CARCINOMA;

ADRENAL GLAND NEOPLASMS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, PAPILLARY; CHROMOSOME ABERRATIONS; DNA MUTATIONAL ANALYSIS; HUMANS; HYPOTHALAMIC NEOPLASMS; MALE; MIDDLE AGED; PROTO-ONCOGENE PROTEINS B-RAF; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; THYROID NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 33846134362     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/thy.2006.16.1293     Document Type: Article

References (42)

1. Davies L, Welch HG 2006 Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 295:2164-2167.
2. Braga-Basaria M, Ringel MD 2003 Beyond radioiodine: a review of potential new therapeutic approaches for thyroid cancer. J Clin Endocrinol Metab 88:1947-1960.
3. Kohn LD, Suzuki K, Nakazato M, Royaux I, Green ED 2001 Effects of thyroglobulin and pendrin on iodide flux through the thyrocyte. Trends Endocrinol Metab 12:10-16.
4. Lazar V, Bidart JM, Caillou B, Mahe C, Lacroix L, Filetti S, Schlumberger M 1999 Expression of the Na + /I - symporter gene in human thyroid tumors: a comparison study with other thyroid-specific genes. J Clin Endocrinol Metab 84:3228-3234.
5. Williams SF, Smallridge RC 2004 Targeting the ERK pathway: novel therapeutics for thyroid cancer. Curr Drug Targets Immune Endocr Metab Disord 4:199-220.
6. Nikiforova MN, Kimura ET, Gandhi M, Biddinger PW, Knauf JA, Basolo F, Zhu Z, Giannini R, Salvatore G, Fusco A, Santoro M, Fagin JA, Nikiforov YE 2003 BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 88:5399-5404.
7. Schlumberger MJ 1998 Papillary and follicular thyroid carcinoma. N Engl J Med 338:297-306.
8. Ain KB 1995 Papillary thyroid carcinoma. Etiology, assessment, and therapy. Endocrinol Metab Clin North Am 24:711-760.
9. Fatourechi V, Hay ID, Mullan BP, Wiseman GA, Eghbali-Fatourechi GZ, Thorson LM, Gorman CA 2000 Are post-therapy radioiodine scans informative and do they influence subsequent therapy of patients with differentiated thyroid cancer? Thyroid 10:573-577.
10. Koutkia P, Safer JD 2001 Adrenal metastasis secondary to papillary thyroid carcinoma. Thyroid 11:1077-1079.
11. Girelli ME, Casara D, Rubello D, Piccolo M, Piotto A, Pelizzo MR, Busnardo B 1993 Metastatic thyroid carcinoma of the adrenal gland. J Endocrinol Invest 16:139-141.
12. Orsolon P, Bagni B, Geatti O, Guerra UP 1996 An unusual adrenal metastasis secondary to Hurthle cell carcinoma of the thyroid. Clin Nucl Med 21:312-315.
13. Yunta PJ, Ponce JL, Prieto M, Lopez-Aznar D, Sancho-Fornos S 2001 Solitary adrenal gland metastasis of a follicular thyroid carcinoma presenting with hyperthyroidism. Ann Endocrinol (Paris) 62:226-229.
14. Ferrer G, Merino T, Ponce M, Pinon S 2002 Unusual metastasis of differentiated thyroid carcinoma [Spanish]. Anales de Medicina Interna 19:579-582.
15. Bell CD, Kovacs K, Horvath E, Smythe H, Asa S 2001 Papillary carcinoma of thyroid metastatic to the pituitary gland. Arch Pathol Lab Med 125:935-938.
16. McCarthy DJ, Karsner HT 1912 Adenocarcinoma of the thyroid, with metastasis to the cervical glands and pituitary: a contribution to the pathology of abnormal fat formation. Am J Med Sci 144:834-847.
17. Fagin JA 2004 How thyroid tumors start and why it matters: kinase mutants as targets for solid cancer pharmacotherapy. J Endocrinol 183:249-256.
18. Dewald GW 2002 Chromosome Study of Autopsy Tissues. Humana Press, Totowa.
19. Furuya F, Shimura H, Suzuki H, Taki K, Ohta K, Haraguchi K, Onaya T, Endo T, Kobayashi T 2004 Histone deacetylase inhibitors restore radioiodide uptake and retention in poorly differentiated and anaplastic thyroid cancer cells by expression of the sodium/iodide symporter thyroperoxidase and thyroglobulin. Endocrinology 145:2865-2875.
20. Ain KB, Tofiq S, Taylor KD 1996 Antineoplastic activity of taxol against human anaplastic thyroid carcinoma cell lines in vitro and in vivo. J Clin Endocrinol Metab 81:3650-3653.
21. Wang CY, Zhong WB, Chang TC, Lai SM, Tsai YF 2003 Lovastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, induces apoptosis and differentiation in human anaplastic thyroid carcinoma cells. J Clin Endocrinol Metab 88:3021-3026.
22. Podtcheko A, Ohtsuru A, Tsuda S, Namba H, Saenko V, Nakashima M, Mitsutake N, Kanda S, Kurebayashi J, Yamashita S 2003 The selective tyrosine kinase inhibitor, STI571, inhibits growth of anaplastic thyroid cancer cells. J Clin Endocrinol Metab 88:1889-1896.
23. Chou T 1991 The median-effect principle and the combination index for quantitation of synergism and antagonism. In: Chou T, Rideout DC (eds) Synergism and Antagonism in Chemotherapy. Academic Press, San Diego, pp 61-102.
24. Sturgis CD, Caraway NP, Johnston DA, Sherman SI, Kidd L, Katz RL 1999 Image analysis of papillary thyroid carcinoma fine-needle aspirates: significant association between aneuploidy and death from disease. Cancer 87:155-160.
25. Mitsutake N, Knauf JA, Mitsutake S, Mesa C, Jr., Zhang L, Fagin JA 2005 Conditional BRAFV600E expression induces DNA synthesis, apoptosis, dedifferentiation, and chromosomal instability in thyroid PCCL3 cells. Cancer Res 65:2465-2473.
26. Godballe C, Asschenfeldt P, Jorgensen KE, Basholt L, Clausen PP, Hansen TP, Hansen O, Bentzen SM 1998 Prognostic factors in papillary and follicular thyroid carcinomas: p53 expression is a significant indicator of prognosis. Laryngoscope 108:243-249.
27. Wilkes D, McDermott DA, Basson CT 2005 Clinical phenotypes and molecular genetic mechanisms of Carney complex. Lancet Oncol 6:501-508.
28. Farrand K, Delahunt B, Wang X-L, McIver B, Hay ID, Goellner JR, Eberhardt NL, Grebe SKG 2002 High resolution loss of heterozygosity mapping of 17p13 in thyroid cancer: Hurthle cell carcinomas exhibit a small 411-kilobase common region of allelic imbalance, probably containing a novel tumor suppressor gene. J Clin Endocrinol Metab 87:4715-4721.
29. Stuart ET, Kioussi C, Aguzzi A, Gruss P 1995 PAX5 expression correlates with increasing malignancy in human astrocytomas. Clin Cancer Res 1:207-214.
30. Barr FG 1997 Chromosomal translocations involving paired box transcription factors in human cancer. Int J Biochem Cell Biol 29:1449-1461.
31. Strehl S, Konig M, Dworzak MN, Kalwak K, Haas OA 2003 PAX5/ETV6 fusion defines cytogenetic entity dic(9;12) (p13;p13). Leukemia 17:1121-1123.
32. Poppe B, De Paepe P, Michaux L, Dastugue N, Bastard C, Herens C, Moreau E, Cavazzini F, Yigit N, Van Limbergen H, De Paepe A, Praet M, De Wolf-Peeters C, Wlodarska I, Speleman F 2005 PAX5/IGH rearrangement is a recurrent finding in a subset of aggressive B-NHL with complex chromosomal rearrangements. Genes Chromosomes Cancer 44:218-223.
33. Stuart ET, Haffner R, Oren M, Gruss P 1995 Loss of p53 function through PAX-mediated transcriptional repression. EMBO J 14:5638-5645.
34. Bergstrom JD, Westermark B, Heldin NE 2000 Epidermal growth factor receptor signaling activates met in human anaplastic thyroid carcinoma cells. Exp Cell Res 259:293-299.
35. Gabler B, Aicher T, Heiss P, Senekowitsch-Schmidtke R 1997 Growth inhibition of human papillary thyroid carcinoma cells and multicellular spheroids by anti-EGF-receptor antibody. Anticancer Res 17:3157-3159.
36. Knight LA, Di Nicolantonio F, Whitehouse P, Mercer S, Sharma S, Glaysher S, Johnson P, Cree IA 2004 The in vitro effect of gefitinib ('Iressa') alone and in combination with cytotoxic chemotherapy on human solid tumours. BMC Cancer 4:83.
37. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA 2004 Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129-2139.
38. Park JW, Yeh MW, Wong MG, Lobo M, Hyun WC, Duh QY, Clark OH 2003 The heat shock protein 90-binding geldanamycin inhibits cancer cell proliferation, down-regulates oncoproteins, and inhibits epidermal growth factor-induced invasion in thyroid cancer cell lines. J Clin Endocrinol Metab 88:3346-3353.
39. Braga-Basaria M, Hardy E, Gottfried R, Burman KD, Saji M, Ringel MD 2004 17-Allylamino-17-demethoxygeldanamycin activity against thyroid cancer cell lines correlates with heat shock protein 90 levels. J Clin Endocrinol Metab 89:2982-2988.
40. George P, Bali P, Annavarapu S, Scuto A, Fiskus W, Guo F, Sigua C, Sondarva G, Moscinski L, Atadja P, Bhalla K 2005 Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3. Blood 105:1768-1776.
41. Nguyen DM, Lorang D, Chen GA, Stewart JHT, Tabibi E, Schrump DS 2001 Enhancement of paclitaxel-mediated cytotoxicity in lung cancer cells by 17-allylamino geldanamycin: in vitro and in vivo analysis. Ann Thorac Surg 72:371-378; discussion 378-379.
42. Vasilevskaya IA, Rakitina TV, O'Dwyer PJ 2003 Geldanamycin and its 17-allylamino-17-demethoxy analogue antagonize the action of Cisplatin in human colon adenocarcinoma cells: differential caspase activation as a basis for interaction. Cancer Res 63:3241-3246.